Lineage Cell Therapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Lineage Cell Therapeutics, Inc. (LCTX) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 0 shares for the 3-month period ending 2015-09-30, per its 10-Q filed 2016-11-04.
Discontinued › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2016-11-04
- Lineage Cell Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2015-09-30 was 0.00 shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month |
|---|---|---|
| 2015-09-30 | 0.00 shares 10-Q · filed 2016-11-04 | 0.00 shares 10-Q · filed 2016-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |